Filing Flows › Veracyte (VCYT) › Q3 2026
Veracyte (VCYT) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Veracyte (VCYT) reported revenue of $152M for the third quarter 2026 (Q3 2026), +15% from a year earlier and +1% from the quarter before. Operating margin was 10.9%, net earnings $31.5M (20.8% of revenue).
Veracyte, Q3 2026: revenue $152M (+15% year over year), operating margin 10.9%, net earnings $31.5M, operating cash flow $40.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $152M | +1% | +15% |
| Gross profit | $107M | -1% | +17% |
| Operating profit | $16.6M | -28% | -28% |
| Net earnings | $31.5M | +24% | +65% |
| Operating cash flow | $40.3M | -12% | -10% |
| Free cash flow | $37.9M | -12% | -10% |
What changed
Revenue was $151.8M in Q3 2026, up 15% year over year and up 1% from the previous quarter. Testing revenue was the largest line at 96% of revenue. Testing revenue added $18.7M year over year (up 15%), 94% of the total change. Biopharmaceutical and other revenue declined 13%.
Gross margin was 70.6%, up 1.4 points from Q3 2025. Operating profit was $16.6M, a 10.9% margin (down 6.5 points year over year). Operating profit fell $6.4M even though revenue rose $19.9M versus Q3 2025, so costs grew faster than sales. Operating expenses grew 32% against revenue growth of 15%. The fastest-growing cost line was Research & development (+101%). Net earnings were $31.5M, up 65% year over year. The effective tax rate was -49.1%. Non-operating items added $4.6M, 22% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $40.3M (down 10% year over year), 128% of net earnings. Non-cash charges added back $6.0M of depreciation and amortization and $14.0M of share-based compensation. Working capital and other items used $11.2M. Capital expenditures of $2.3M left free cash flow of $37.9M.
Questions
What was Veracyte's revenue in the third quarter 2026?
Veracyte (VCYT) reported revenue of $152M for the third quarter 2026 (Q3 2026), +15% from a year earlier and +1% from the quarter before.
Was Veracyte profitable in the third quarter 2026?
Operating profit was $16.6M (10.9% of revenue) and net earnings $31.5M.
Source: Veracyte 10-Q on SEC EDGAR.